Simmons Hanly Conroy Named Pharmaceutical Litigation Finalist by NLJ’s 2023 Elite Trial Lawyers Awards

National Trial Lawyers Press Release for SHC

ALTON, Ill., and NEW YORK – Simmons Hanly Conroy, one of the nation’s largest mass tort firms and a national leader in the legal representation of mesothelioma patients and their families, is pleased to announce that the National Law Journal’s (NLJ’s) 2023 Elite Trial Lawyers Awards has selected the firm as finalist in the Pharmaceutical Litigation category.

Jayne ConroyIn addition, the Elite Trial Lawyers Awards selected the firm’s Named Shareholder Jayne Conroy as one of this year’s Elite Women of the Plaintiff’s Bar. All awards winners and finalists will be recognized at a ceremony July 13 in New York City.

“It is an honor for Simmons Hanly Conroy to be named by the National Law Journal’s Elite Trial Lawyers Awards as among the top plaintiffs firms for pharmaceutical litigation,” said Larry Nassif, Managing Shareholder of Simmons Hanly Conroy. “Part of our firm’s mission always has been to hold drug companies and other big corporations accountable for selling dangerous drugs and medical devices without properly warning consumers of their serious side effects. We are proud of our track record of helping people who have been hurt when these companies choose profits over consumers’ safety.”

Since 1999, Simmons Hanly Conroy attorneys have recovered nearly $10 billion on behalf of clients in verdicts and settlements.

Started in 2015, the Elite Trial Lawyers Awards recognize lawyers and law firms’ outstanding plaintiffs work in high-stakes bench or jury trials or in major settlements. Elite Trial Lawyers Awards winners must have scored a significant win during the contest period and demonstrate an impressive track record of wins over the last three to five years.

Finalist firms also must have devoted at least 50% of their litigation resources to plaintiffs work and shown innovative approaches to case resolution.